Gene therapy represents a transformative approach to treating neurodegenerative diseases by delivering therapeutic genetic material into target cells to modify disease processes at their molecular root. This technology offers the potential to address underlying genetic causes of conditions like Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS)[@gene2023][@aav2022].
Mechanism of Action
Gene therapy for neurodegenerative diseases employs several delivery strategies:
Viral Vectors
Adeno-associated viruses (AAVs): Most commonly used vectors due to their safety profile and ability to transduce both dividing and non-dividing cells. AAV vectors can deliver genes to specific brain regions through stereotactic injection[@adenoassociated2021].
Lentiviruses: Integrate into the host genome, providing long-term expression, but carry some oncogenic risk.
Adenoviruses: High cargo capacity but elicit stronger immune responses.
Non-Viral Methods
Lipid nanoparticles (LNPs): Emerging as safer alternatives with improved delivery profiles.
Electroporation: Uses electrical pulses to facilitate gene uptake.
CRISPR-based editing: Enables precise genetic modifications including gene knock-in, knock-out, and correction[@crisprcas2023].
Target Mechanisms
Gene replacement: Delivering functional copies of mutated genes (e.g., GBA for Parkinson's disease)
Gene silencing: Using RNAi or antisense oligonucleotides to reduce expression of toxic proteins
Neuroprotective factor delivery: Expressing growth factors like BDNF, GDNF, or NGF
Metabolic enzyme supplementation: Delivering enzymes to correct metabolic deficits
Advantages
Potential for disease modification: Unlike symptomatic treatments, gene therapy can target underlying disease mechanisms
Long-lasting effects: Single administration may provide years of therapeutic benefit
Precise targeting: Can be directed to specific brain regions or cell types
Treatment of genetic forms: Particularly valuable for monogenic forms of neurodegenerative diseases
Reduced treatment burden: May eliminate need for frequent dosing
Challenges
Blood-brain barrier (BBB): Most vectors cannot cross the BBB, requiring invasive direct brain delivery
Immune response: Pre-existing immunity to viral vectors can reduce efficacy
Limited cargo capacity: AAV vectors have small packaging limits (~4.7 kb)
Off-target effects: Particularly for CRISPR-based approaches
Delivery distribution: Achieving uniform coverage of target brain regions remains challenging
Safety concerns: Risk of insertional mutagenesis with integrating vectors
Cost: Currently extremely expensive, with prices exceeding $1 million per treatment
Current Development Stage
Gene therapy for neurodegenerative diseases is in various stages of clinical development:
Parkinson's Disease
AAV-GAD gene therapy (Northwest Biotherapeutics): Completed Phase II trials for advanced [PD](/diseases/parkinsons-disease)
AADC gene therapy (Paxmedica/Prenatal): In clinical trials for aromatic L-amino acid decarboxylase deficiency, with applications to [PD](/diseases/parkinsons-disease)
[GBA](/genes/gba) gene therapy: Preclinical and early clinical stages for GBA-associated [PD](/diseases/parkinsons-disease)
Alzheimer's Disease
AAV-based BACE1 silencing: Several programs have been discontinued due to safety concerns
[Unknown, Gene therapy for neurodegenerative diseases: progress and challenges (Nature Reviews Drug Discovery, 2023) (2023)](https://doi.org/10.1038/s41573-023-00701-4)